Exhibit 99.2

Ticker: MRIC

Investor Presentation

January 7th, 2016

Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI

c 2015 MRI INTERVENTIONS, INC. | 1

Forward Looking Statements

Certain statements in this presentation may constitute forward-lookingstatements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions’ actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions’ forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; availability and adequacy of reimbursement from third party payors for procedures utilizing our products; the sufficiency of our cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; the impact of the commercial and credit environment on us and our customers and suppliers; and our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, our ClearTrace system. More detailed information on these and additional factors that could affect MRI Interventions’ actual results and the timing of events are described in its filings with the Securities and Exchange Commission. Except as required by law, MRI Interventionsundertakesnoobligationtopubliclyupdateorreviseanyforward-looking statementsmadeinthispresentationtoreflectanychangeinMRIInterventions’expectationsoranychange inevents,conditionsorcircumstancesonwhichanysuchstatementsarebased.

c 2015 MRI INTERVENTIONS, INC. | 2

MRI Interventions Opportunity

Market potential

Market Potential 55,000 potential ClearPoint procedures across multiple therapies

Electrode placement for deep brain stimulation

NavigationSystem

Laser Ablation for ablation of epileptic foci or Brain Tumors

forMultiple

Brain Tumor Biopsy for deep seated tumors

Therapies

Precise Drug Delivery to target lesions

Opportunityto Area of interest to large medical device companies

AttractMultiple Medtronic, St. Jude and Boston Scientific investing in neuro market Players MRI Scanner Companies embracing MRI-guided therapies

Drug Companies pursuing direct delivery

Focused commercial effort in neurosurgery; FDA/CE approved products

Uniquely Delivery platform for multiple therapies Positioned Established, proprietary IP position

Recent restructuring complete

c 2015 MRI INTERVENTIONS, INC. | 3

MRI Interventions:

Real Time MRI Guided Surgery

Firstto-markettechnologyplatformenabling altime MRI guideded surgery; Acleared, CE-marked and nd40+ ClearPoint sites

Focused commercialization of neuro platform underway; recent restructuring complete

Attractive razor/razorblade business model with strongng potential margins

Compatiblewithall major MRI manufacturers; Interoperability w/ Medtronic, Monteris, neuro roducts

Established intellectual property portfolio

Professionalmanagementteamwithrelevantmedicaldevicecommercialization experience: Intuitive, Medtronic, Kyphon, Boston Scientific, ev3, Edwards Lifescience, Cordis

c 2015 MRI INTERVENTIONS, INC. | 4

Leadership A History of Med Device Experience

Key Management

Executive Title Prior Experience

Frank Grillo President, CEO

Peter Piferi COO

Wendelin Maners VP Marketing

Robert Korn VP Sales

Hal Hurwitz CFO

Board of Directors

Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Grillo, Exec Chair Richards CEO

Jack Spencer Charles Koob Andrew Rooke

Major 2015 MRI INTERVENTIONS, INC. | 5

Investor

Technology: ClearPointR Neuro Navigation System

Navigation System consisting of Integrated Devices and Software for Real-Time, MRI Guided, Minimally Invasive Neurosurgical Procedures

Visualize Verify Confirm

Identify target Observe progress to target Confirm precise placement at target

c 2015 MRI INTERVENTIONS, INC. | 6

Without ClearPoint, minimally invasive neuro procedures are performed “blind”

Conventional Stereotactic Procedure ClearPointnt Neuro Procedure

No real-time visualization

Nextt generationn platform enabling realtime, MRIIguided, minimally invasive brain surgery

c 2015 MRI INTERVENTIONS, INC. | 7

ClearPointR Neuro Navigation System

1.5T or 3T MR Scanners, also works in intraop MRI Suites

MRI Safe Disposable Components:

SmartGridR and SmartFrameR Integrated ClearPoint Targeting and Trajectory Precision

ClearPointR Drape provides sterile procedural field in any diagnostic or intraoperative MRI scanner

Emory University Hospital UCSF Medical Center University of Pittsburgh Brigham and Women’s Medical Center Hospital*

* Image courtesy of IMRIS

Integrates with All Major Scanner Platforms

c 2015 MRI INTERVENTIONS, INC. | 8

ClearPoint Procedure Overview

Target Selection & Entry Planning

VIDEO

c 2015 MRI INTERVENTIONS, INC. | 9

ClearPoint Procedure Overview

SmartFrameR Trajectory Guide Trajectory Alignment & Device Insertion

VIDEO

SmartFrameR Hand Controller

c 2015 MRI INTERVENTIONS, INC. | 10

ClearPoint Procedure Overview

Delivery of Neurological Therapy

Drug Deliveryry⁽¹⁾ Electrode Placement Laser Ablationn⁽²⁾

VIDEO VIDEO VIDEO

Drug Delivery¹ Electrode Placement Laser Ablation²

(1)Drug Delivery -The SmartFlowR cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic agents, and delivery of agents to other areas of the brain, using the SmartFlow cannula is investigational.

(2)Laser Ablation -MR Thermometry is an MRI-based functionality available on most MR scanner platforms and it is a feature built into products from several third party vendors. The ClearPoint system enables MRI-guided procedures and allows physicians to use this inherent MR capability during a procedure.

c 2015 MRI INTERVENTIONS, INC. | 11

ClearPoint Hospital Economics

Increase Patients

Better potential patient experience provides hospitals the opportunity to reach additional patient populations that may otherwise forego surgery

65% of eligible DBS patients refuse treatment, due to fear of surgery⁽¹⁾

Established, Attractive Reimbursement

Move procedures from the more expensive OR to the less expensive MR suite, with equivalent reimbursement

Improved Utilization of Existing MRI’s

1 hour of MR Scanner time used for diagnostic imaging could generate $1,200⁽²⁾

1 hour of MR scanner time used for a ClearPoint procedure could generate $5,275⁽³⁾

Utilizes existing MRI’s already in hospital

(1) Medtronic Investor Presentation, June, 2014

(2) Estimated average US hospital-based MRI suite revenue per hour for outpatient diagnostic scans, based on data gathered by MRI Interventions. Excludes professional fees. Actual revenues will vary by hospital, procedure and payor.

(3) Based on a weighted average payment to MRI Interventions’ customers (as of September 2014) for an electrode placement procedure for Medicare and private insurance patients, calculated by MRI Interventions using a payor mix weighted 67% to average Medicare reimbursement and 33% to average private insurance reimbursement. Average Medicare reimbursement calculated as the weighted average Medicare payment for MRI Interventions’ customers (as of September 2014) for an electrode placement procedure under MS-DRGs 025, 026 and 027. Average private insurance reimbursement calculated as 1.5x Medicare reimbursement, based on published data. Hourly amount assumes 4.5 hour procedure duration. Excludes professional fees. Actual revenues will vary by hospital, procedure and payor.

c 2015 MRI INTERVENTIONS, INC. | 12

Multi-Therapy MRI-Guided Navigational System

Notable Neurosurgeon Supporters

Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen, Jr. Dr KrysBankiewicz DrRussLonser ASSFN Past President UCSF & VA Emory University Mayo Clinic - Bankiewicz Lab, UCSF OSU NIH

Jacksonville

Published Peer-Reviewed Journal Support

Compatible With Multiple Therapies

Visualase^R

SmartFlow™ cannula for local drug delivery

c 2015 MRI INTERVENTIONS, INC. | 13

Patented Intellectual Property

Close to 100 issued patents around the world

40+ U.S. 50+ OUS 50+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications

Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrameR trajectory guide; other ClearPointR disposable components; active intracranial probes; MRI-compatible catheters; MRI-safety technology

Key ClearPoint-related patents do not begin to expire until 2027

c 2015 MRI INTERVENTIONS, INC. | 14

Patient Impact

Martin’s Story

ClearPoint-Enabled Electrode Placement

VIDEO

c 2015 MRI INTERVENTIONS, INC. | 15

Patient Benefit Minimally Invasive Procedure

7days after ClearPoint procedure Arrow Indicates Surgery Site

ERVENTI INC. | 16

ClearPoint Drug Delivery

MR visualization of neuro target

MR-guided placement of catheter

Therapeutic agent delivered under MR-guidance*

Specialized drug delivery cannula’s / catheters

Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery to be performed with a high level of precision, predictability, and safety.

Drug infusion is visible real time under MRI

* CAUTION: SmartFlow Cannula is approved for injection of Cytarabine or removal of CSF from the ventricles during intracranial procedures. c 2015 MRI INTERVENTIONS, INC. | 17

Uses other than the approved indication are limited by Federal law to investigational use.

MRIC’s Unique Opportunity for Drug Delivery

Major Challenges in Delivering Drugs to the Brain

- Blood brain barrier blocks systemic delivery of almost all drugs up to 98% of small molecules

- Direct injection without ClearPoint is blind, so target can frequently be missed

- Neopharm Trial-51% of 572 catheters failed to meet all positioning criteria

Major Benefits of Drug Delivery with ClearPoint

- Neurosurgeon can see that target is reached

- Eliminates the blood brain barrier issue; Reduces/eliminates unwanted systemic side effects; Reduces dosage levels(as little as 1/300th of systemic volumes)

Business Model MRIC Partners with Drug Companies and Researchers

- MRIC provides ClearPoint; Drug company provides drug candidate

- Drug company/sponsor pays for trial

- If drug is approved, MRIC gets device revs (~$7000/case); Drug co gets drug revs

c 2015 MRI INTERVENTIONS, INC. | 18

The ClearPoint Difference

Without ClearPoint (Stereotactic) With ClearPoint

Nodirectvisualization;Performedinanoperating Directhighresolutionvisualization;Performedin room an MRI Suite

Accuracy to target based on prior images Highly accurate, based on real time images Patient may be awake forown brain surgery(1) Patient may be undergeneralanesthesia⁽¹⁾ Long OR time for the patient Can be up to 8 hours Shorterprocedures Can be 3 hours or less

May require OR and MRI for same procedure (laser MRI only procedure -One procedure, one place ablation)

Poor economics for hospital and physician Attractive economics for hospital and physician

Better for Patients Better for Surgeons Better for Hospitals

(1) Microelectrode recording and macrostim are processes that involve listening to neuronal firings (i.e., physiological recordings) and observing physiological responses to stimuli during brain surgery. In connection with our 510(k) clearance in 2010, the FDA requested a warning within ClearPoint’s Instructions for Use based on the lack of data with respect to deep brain stimulation (DBS) procedures. The warning states that the ClearPoint system, alone, should not be usedtoguide a DBS lead to a specific brain target and that final placement of DBS leads requires physiological recordings to confirm that they are located in the correct brain targetand functioning as intended.

c 2015 MRI INTERVENTIONS, INC. | 19

ClearPoint Revenue Model

BUSINESS MODEL RAZOR / RAZORBLADE

ClearPoint Hardware/Software: $100,000 -$150,000 ASP

ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reimbursement codes

c2015MRIINTERVENTIONSINC. 20

Growing the ClearPoint Footprint

Installed Base of 39 sites in the US

September, 2015

c 2015 MRI INTERVENTIONS, INC. | 21

ClearPoint US Market Opportunity

Parkinson’s Epilepsy Brain Tumors

Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis)

Prevalence Drug Treatment 125,000 264,000 Resistant (DTR)

7,500 18,000 Resections: 80,000

Incidence DTR

Stereotactic Biopsy: 10,000

Electrode Laser Ablation Biopsy / Laser Ablation /

ClearPoint Enabled Therapy

Placement (DBS) RNS¹ Drug Delivery

Potential ClearPoint 12,500 28,000 14,500 Procedures, Annually²

55,000+ Potential Procedures Per Year

Note: Prevalence and Incidence based on either market research conducted by a third party on behalf of MRI Interventions or researchconducted by MRI Interventions of publicly available sources.

(1) Responsive neurostimulation device (RNS)

(2) Potential Annual ClearPoint Procedures based upon 5% of prevalence and 85% of incidence; Potential Annual ClearPoint Procedures for brain tumors based on market research conducted by a third party on behalf of MRI Interventions.

c 2015 MRI INTERVENTIONS, INC. | 22

ClearPoint Future Opportunities

Multiple Therapies for Future Growth

Patient Treatment Resistant ClearPoint Enabled

Current Status Neuro Disorder Population Patient Population Therapy

Dystonia 250,000 25,000 DBS Active Use, HDE

OCD 3,300,300 100,000 DBS Active Use, HDE

SevereDepression 6,000,000 1,200,000 DBS IDE Trials (DBS)

Parkinson’s

1,500,000 125,000 Drug Delivery Clinical Trials Phase 1

Disease

Brain Tumors Clinical Trials Phase 1 11,000 11,000 Drug Delivery

(GBM)

Huntington’s 30,000 30,000 Drug Delivery Pre-Clinical

Pre-Clinical ALS 30,000 30,000 Drug Delivery

Alzheimer’s 5,400,000 500,000 DBS Research

c 2015 MRI INTERVENTIONS, INC. | 23

ClearPoint Consumable Revenues

Consumables

$1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000

$-

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2013 2014 2015

c 2015 MRI INTERVENTIONS, INC. | 24

Total Revenue, 2013 -2015

$1,600,000

Total Revenue

$1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000

$-

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2013 2014 2015

Consumables Capital / Service Other

c 2015 MRI INTERVENTIONS, INC. | 25

Cash Flow From Operations 

$0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000

-$2,500,000 

-$3,000,000 

Q2 Q3 Q4 Q1 Q2 Q3 

2014 2015 

© 2015 MRI INTERVENTIONS, INC. | 26

Commercial Priorities

Focus on adding surgeons at existing accounts

ncrease

Target high volume sites, including epilepsy and tumor neurosurgeons within each Utilization account; gain greater share of their procedures

Add Clinical Specialists and sales reps to commercial team; compensate for utilization growth

Increase peer-to-peer events, presence at trade shows

Enhance Highlight existing data on ClearPoint applications to neurologists and neurosurgeons Communication Communicate value proposition across procedures:

Accuracy

Real time visualization

Improved workflow

Increase patient volume

Identify highest volume potential accounts across multiple procedures

ExpandAccountpand Acco

Support local hospital marketing efforts

Base Capitalize on interest in drug delivery to expand in oncology accounts

Add sales reps

Tightly control working capital, consumption of cash

Achieve Cash

Hire additional personnel only in key functions commercial team; engineering

Breakeven

c 2015 MRI INTERVENTIONS, INC. | 27

R&D Priorities

Seek significant upgrade to existing software; includes Software 2.0 real time fusion, enhanced graphic and User Interface

Technology licenses near complete with three additional software companies for this effort

Through partnership(s), expand our products OR SmartFrame and brand into the operating room for CT based neuro procedures

Establish additional drug delivery partnerships, Drug Delivery and participate in additional clinical trials

Become the neuro drug delivery device partner of choice

Continue to enhance product line with a focus Bolt Driver

Procedure on procedure simplification and consistency for

Enhancements

Laser Ablation

c 2015 MRI INTERVENTIONS, INC. | 28

At the Center of an Emerging Industry Trend

ClearPoint ClearPoint MRICisatthepointof

Electrode Laser Catheter

Placement Placement convergenceinan

industrytrendimpacting

Real Time

MRI- someofthemost

ClearPoint Guided ClearPoint

Direct Drug Procedures Performed influentialand

Delivery in MRI innovativemedical

Scanners

ClearTrace devicecompanies

Ablation and in the world Drug Delivery

In Development

c 2015 MRI INTERVENTIONS, INC. | 29

Ticker: MRIC

MRI Interventions, Inc.

Irvine, CA 949.900.6833 mriinterventions.com

Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI

c 2015 MRI INTERVENTIONS, INC. | 30